Literature DB >> 8485829

Cardiac mechanics during development of heart failure. SOLVD Investigators.

H Pouleur1, M F Rousseau, C van Eyll, J Melin, M Youngblood, S Yusuf.   

Abstract

BACKGROUND: The changes in myocardial performance responsible for the progression from a stage of asymptomatic left ventricular dysfunction toward overt congestive heart failure are still poorly understood. Accordingly, using invasive methods, we examined the differences in baseline left ventricular function between a subgroup of patients enrolled in the treatment arm (presence of congestive heart failure) and in the prevention arm (asymptomatic patients) of the Studies of Left Ventricular Dysfunction. METHODS AND
RESULTS: High-fidelity left ventricular pressures and frame-by-frame angiographic volumes were simultaneously obtained under baseline conditions in 65 patients with left ventricular ejection fraction < or = 35%. Sixteen patients had New York Heart Association congestive heart failure (class II or III), whereas the remaining 49 patients had no clinical signs of heart failure and did not receive therapy for this syndrome. A second set of data was obtained an average of 12.4 months later in 42 patients. The group with heart failure had significantly greater end-diastolic and end-systolic volumes than the asymptomatic group (both p < 0.001), but the stroke index at rest was similar in both groups. Accordingly, ejection fraction was significantly lower in the heart failure group (19.6 +/- 7.0% versus 26.3 +/- 7.2%; p < 0.02). Left ventricular end-diastolic pressure was greater and peak +dP/dt was lower in heart failure patients, but the difference did not reach statistical significance after Bonferroni correction for multiple comparisons. Moreover, the individual end-systolic stress/end-systolic volume data of the heart failure patients fell within the 95% confidence interval of the relation observed in the patients without heart failure both at baseline and after 1 year of follow-up irrespective of their changes in functional status. It was also noted that during follow-up, the changes in end-diastolic and end-systolic volumes correlated linearly, as if both dimensions always shifted in parallel, whereas alterations in contractility primarily influence end-systolic volume.
CONCLUSIONS: These observations are compatible with the hypothesis that a depression in the mechanical performance of the viable myocardial areas is not the major determinant for the progression from asymptomatic to symptomatic left ventricular dysfunction. Abnormalities in left ventricular diastolic distensibility, on the other hand, might underlie the progressive ventricular dilation and create a vicious cycle through the afterload mismatch.

Entities:  

Mesh:

Year:  1993        PMID: 8485829

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.

Authors:  R S McKelvie; C R Benedict; S Yusuf
Journal:  BMJ       Date:  1999-05-22

Review 2.  Left ventricular size and shape: determinants of mechanical signal transduction pathways.

Authors:  Douglas L Mann
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

3.  MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.

Authors:  Srikanth Givvimani; Neetu Tyagi; Utpal Sen; Paras K Mishra; Natia Qipshidze; Charu Munjal; Jonathan C Vacek; Oluwasegun A Abe; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2010-05       Impact factor: 4.076

Review 4.  Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction heart failure.

Authors:  Veli K Topkara; Srikanth Kondareddy; Douglas L Mann
Journal:  Curr Heart Fail Rep       Date:  2009-12

Review 5.  The ever expanding spectrum of ischemic left ventricular dysfunction.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.